House Dust Mite Disease Market Size in the 7MM is projected to grow at a significant CAGR by 2034, estimates DelveInsight

DelveInsight's "House Dust Mite Disease Market Insight, Epidemiology and Market Forecast - 2034" report delivers an in-depth analysis of House Dust Mite Disease epidemiology, market, and clinical development understanding, Addition to this report provides historical and forecasted epidemiology and market data as well as a detailed analysis on the House Dust Mite Disease therapeutics market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Download DelveInsight's comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ https://www.delveinsight.com/sample-request/house-dust-mite-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the House Dust Mite Disease Market Report
• In December 2025- ALK-Abelló A/S conducted a trial aims to evaluate efficacy of the house dust mite (HDM) SLIT-tablet compared to placebo in Chinese participants aged 12-65 with HDM allergic rhinitis/rhinoconjunctivitis with or without asthma. Efficacy will be assessed based on the total combined rhinitis score during the last 4 weeks of treatment. The trial is a randomised, double-blind, parallel-group, placebo-controlled, multi-site, phase III trial conducted in China. The treatment period will be 24-28 weeks.
• In 2024, the diagnosed prevalent population of asthma in the 7MM was approximately 113 million. This number is expected to rise through 2034, driven by advances in complement biology, improved diagnostics, and wider use of genetic testing, complement assays, and multidisciplinary biopsy evaluation.
• The diagnosed prevalent population of allergic rhinitis, in the United States, was found to be 25 million in 2024.
• In 2024, the prevalent population of HDMD was estimated at 40 million cases. This prevalence is influenced by widespread exposure to HDM in indoor environments, increasing rates of atopy, urbanization, and changing lifestyles that favour prolonged indoor activities.
• The female predominance in allergic diseases in adults may be related to hormonal influences like estrogen that modulate immune responses, increasing sensitivity to HDMD and other allergens, coupled with environmental exposure patterns, and possibly health behaviour differences.
• In EU4 and the UK, among allergen-specific diagnosed HDM cases, Der p 2 was the most prevalent allergen, detected in approximately 92% of allergic individuals, while Der p 23 accounted for a lower share, at nearly 82%.
• The leading House Dust Mite Disease Companies such as ALK-Abello, Stallergenes Greer, HAL Allergy, Probelte Pharma, Inmunotek, T-Balance Therapeutics and others.
• Promising House Dust Mite Disease Therapies such as SUBLIVAC FIX Mite mixture, hdmASIT+TM, Tregalizumab, CYT005-AllQbG10, Toleromune HDM, SLITone(TM) Dermatophagoides mix, Acaroid and others.

Access DelveInsight's in-depth market analysis and strategic insights today! Click here for more @ https://www.delveinsight.com/sample-request/house-dust-mite-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

House Dust Mite Disease Epidemiology Segmentation in the 7MM
• Total Prevalent Population of HDMD
• Total Diagnosed Prevalent Population of HDMD
• Gender-specific Diagnosed Prevalent Population of HDMD
• Allergen-specific Diagnosed Prevalent Population of HDMD
• Total Treated Cases of HDMD

Download the report to understand which factors are driving House Dust Mite Disease epidemiology trends @ https://www.delveinsight.com/sample-request/house-dust-mite-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

House Dust Mite Disease Marketed Drugs
• Dermatophagoides farinae and Dermatophagoides pteronyssinus (ODACTRA/ACARIZAX/MITICURE): ALK-Abello
ODACTRA is an allergen extract indicated as immunotherapy for the treatment of HDM-induced allergic rhinitis, with or without conjunctivitis.

• House dust mite allergen extract (ACTAIR/ORYLMYTE/AITMYTE): Stallergenes Greer
ACTAIR is Stallergenes Greer's sublingual immunotherapy tablet for the treatment of patients suffering from HDM-induced allergic rhinitis.

House Dust Mite Disease Emerging Drugs
• House Dust Mite Allergy Vaccine (PURETHAL Mites): HAL Allergy
PURETHAL Mites is a subcutaneous allergen immunotherapy treatment that uses a chemically modified extract of HDMs (Dermatophagoides pteronyssinus and Dermatophagoides farinae) adsorbed to aluminum hydroxide. The drug is currently undergoing a Phase III clinical trial.

• Alternaria Allergy Immunotherapy (BELTAVAC): Probelte Pharma
BELTAVAC is a type of subcutaneous immunotherapy for Alternaria mold allergy. Probelte Pharma has developed a safer allergen immunotherapy treatment based on a dust mite (Dermatophagoides pteronyssinus) allergen extract that has been modified through polymerization with glutaraldehyde. The drug is currently undergoing a Phase III clinical trial.

Get expert insights and forecasts-download now! @ https://www.delveinsight.com/sample-request/house-dust-mite-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

House Dust Mite Disease Market Outlook
The management of HDMD primarily relies on symptomatic control using off-label and supportive therapies, underscoring the lack of approved, disease-modifying options. Current treatment strategies include antihistamines, intranasal corticosteroids, leukotriene receptor antagonists, and allergen immunotherapy (AIT) formulations. Despite being a mainstay, AIT's efficacy varies across individuals, and its use is often limited by long treatment duration, adherence challenges, and safety concerns such as systemic allergic reactions.

House Dust Mite Disease Drugs Market
Most approved and emerging candidates for HDMD therapy fall under the immunomodulator class; however, tregalizumab is the only agent that specifically belongs to the anti-CD4 subclass. Anti-CD4: Anti-CD4 monoclonal antibodies, such as tregalizumab, bind selectively to the CD4 receptor on T cells and modulate their activity without causing depletion. This interaction downregulates overactive Th2 responses while enhancing regulatory T-cell (Treg) function, restoring immune tolerance to HDM allergens. By dampening the excessive cytokine release and suppressing allergen-specific T-cell activation, anti-CD4 agents help reduce inflammation, mucus production, and tissue remodeling associated with chronic allergic disease. Thus, anti-CD4 therapy represents a targeted approach to reprogram immune balance in HDMD, offering potential benefits in reducing symptom severity and preventing disease progression, particularly in patients unresponsive to standard immunotherapy.

House Dust Mite Disease Treatment Market
The treatment landscape for HDMD has recently begun to evolve with the development of targeted immunotherapies and peptide-based vaccines designed to desensitize patients while minimizing adverse reactions. The approval of ODACTRA marked a milestone as the first SLIT tablet for HDM-induced allergic rhinitis, yet its black box warning and limited pediatric safety data highlight ongoing challenges in optimizing long-term management. Drugs including PURETHAL Mites, BELTAVAC, and MM09 are in advanced phases of clinical development; however, recent updates on their progress are limited, indicating a lack of notable developmental activity. Since none of these candidates have yet advanced to regulatory submission or commercialization, it suggests that timelines for market entry remain uncertain. Additionally, Tregalizumab, currently in mid-stage development, demonstrates innovative therapeutic potential through its unique specificity in selectively activating Tregs and is supported by well characterized pharmacokinetic profiles, highlighting its innovative therapeutic potential.

From market size to emerging drugs-find it all in our latest report. Read now! @ https://www.delveinsight.com/sample-request/house-dust-mite-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the House Dust Mite Disease Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• House Dust Mite Disease Companies- ALK-Abello, Stallergenes Greer, HAL Allergy, Probelte Pharma, Inmunotek, T-Balance Therapeutics and others.
• House Dust Mite Disease Pipeline Therapies- SUBLIVAC FIX Mite mixture, hdmASIT+TM, Tregalizumab, CYT005-AllQbG10, Toleromune HDM, SLITone(TM) Dermatophagoides mix, Acaroid and others.
• House Dust Mite Disease Therapeutic Assessment: House Dust Mite Disease Current Marketed and House Dust Mite Disease Emerging Therapies
• House Dust Mite Disease Market Dynamics: House Dust Mite Disease market drivers and House Dust Mite Disease market barriers
• House Dust Mite Disease Unmet Needs, KOL's views, Analyst's views, House Dust Mite Disease Market Access and Reimbursement

Table of Contents
1. Key Insights
2. Report Introduction
3. House Dust Mite Disease Market Overview at a Glance
4. House Dust Mite Disease Methodology
5. House Dust Mite Disease Executive Summary
6. House Dust Mite Disease Background and Overview
7. House Dust Mite Disease Treatment and Management
8. House Dust Mite Disease Epidemiology and Patient Population
9. House Dust Mite Disease Patient Journey
10. Emerging House Dust Mite Disease Therapies
11. House Dust Mite Disease Market Analysis
12. House Dust Mite Disease KOL Views
13. House Dust Mite Disease SWOT Analysis
14. House Dust Mite Disease Unmet Needs
15. House Dust Mite Disease Market Access and Reimbursement
16. Appendix
17. DelveInsight Capabilities
18. Disclaimer

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.